Merck & Co Inc

Latest Merck & Co Inc News and Updates

  • Merck logo over virus illustration
    Healthcare

    Merck Sells COVID Pill to U.S. at $700 Per Treatment Course

    Merck is requesting emergency use for its COVID-19 treatment pill. How much will the drug cost?
    By Rachel Curry
  • A person walking past the Merck logo on a wall
    Healthcare

    Why 2021 Could Be a Very Healthy Year for Merck Stock

    Merck stock rose 8 percent on Oct. 1, and was higher in premarket trading on Oct. 4. What’s the forecast for MRK stock?
    By Ambrish Shah
  • Merck sign
    News

    Study Shows Merck Antiviral Drug Is Effective in Treating COVID-19

    A recent study found that Merck's antiviral drug is effective in treating COVID-19. The jury is still out on whether the drug is as effective as the vaccine.
    By Danielle Letenyei
  • uploads///Article
    Company & Industry Overviews

    How Did AstraZeneca’s CVMD Franchise Perform in 2014?

    In 2014, AstraZeneca’s CVMD franchise generated nearly $9.8 billion, a 11% rise in sales as compared to $8.8 billion in 2013.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Merck & Co.’s Animal Health Segment

    The revenues of Merck & Co.’s Animal Health segment have improved due to increased sales in the Companion Animal Products segment.

    By Mike Benson
  • uploads///thermometer _
    Company & Industry Overviews

    Wall Street Analysts Are Mostly Positive on Merck in September

    Of the 19 analysts tracking Merck (MRK) stock in September, four recommended a “strong buy” while ten analysts recommended a “buy.”

    By Daniel Collins
  • uploads///Graph
    Company & Industry Overviews

    Merck Expects Modest Revenue Growth in Fiscal 2016

    Merck provided revenue guidance of $39.7 billion–$40.2 billion in 2016. It expects negative foreign exchange fluctuations to reduce its fiscal 2016 revenue.

    By Margaret Patrick
  • uploads///Novo RV multiples
    Earnings Report

    Is Novo Nordisk Trading at a Discount or Premium?

    For the last five years, Novo Nordisk (NVO) has been trading at higher multiples when compared with peers.

    By Jillian Dabney
  • uploads///Chart
    Company & Industry Overviews

    A Look at Johnson & Johnson’s Post-2Q17 Valuation

    Headquartered in New Jersey, Johnson & Johnson (JNJ) is one of the largest pharmaceutical companies, with its products sold in over 200 countries worldwide. This series will look at how it has performed since its 2Q17 earnings announcement.

    By Mike Benson
  • uploads///Graph
    Company & Industry Overviews

    What Are Analysts’ Recommendations for Merck in 2017?

    For 2016, Merck & Co. (MRK) reported revenue close to $39.8 billion, a year-over-year (or YoY) rise of ~1%. New product launches have played major roles in boosting Merck’s 2016 revenue.

    By Margaret Patrick
  • uploads///Chart
    Earnings Report

    Johnson & Johnson’s Valuation Cheat Sheet

    On January 26, 2017, the company was trading at a forward PE of ~15.8x. Based on the last five years’ multiple range, JNJ’s current valuation is neither high nor low.

    By Mike Benson
  • uploads///Article
    Company & Industry Overviews

    Sanofi Increased Net Revenues in 2014

    Sanofi’s net revenues increased by ~2.5% to 33.8 billion euros in 2014, as compared to $23.2 billion in 2013.

    By Mike Benson
  • uploads///Graph
    Company & Industry Overviews

    What Analysts Think about Bristol-Myers Squibb

    Of 28 analysts covering BMY’s stock, 42.3% gave it a “buy” recommendation, while 50.0% gave it a “hold” recommendation. Only 7.7% rated it as a “sell.”

    By Margaret Patrick
  • uploads///ANR
    Company & Industry Overviews

    Analysts’ Expectations for Sanofi

    According to a March 3, 2016, Bloomberg consensus of five brokerage firms, 60% of brokerage firms rated Sanofi as a “buy,” while 40% of the broker firms rated the company as a “hold.”

    By Jillian Dabney
  • uploads///Graph
    Company & Industry Overviews

    Celgene’s Revlimid Expected to Post Strong Revenue in 2017

    According to unaudited financial results published by Celgene (CELG) on January 9, 2017, Revlimid sales for 2016 are about $7.0 billion, a YoY rise of about 20.0%.

    By Margaret Patrick
  • uploads///Article
    Earnings Report

    Novartis’s Adjusted Earnings per Share Declined 7% in 2Q15

    Novartis (NVS) posted its 2Q15 earnings on July 21, 2015. The company achieved adjusted EPS of $1.27 for 2Q15, ~7% lower than in 2Q14.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    What Analysts Project for Eli Lilly in 3Q17

    For 3Q17, analysts estimate that Eli Lilly will post EPS of $1.03 on revenues of $5.5 billion.

    By Mike Benson
  • uploads///Pfizer revenues
    Company & Industry Overviews

    How Did Pfizer Perform in 3Q17?

    In 3Q17, Pfizer (PFE) generated revenues of $13.2 billion, an increase of ~1% on a year-over-year (or YoY) basis and a 1% increase on a quarter-over-quarter basis.

    By Daniel Collins
  • uploads///Chart
    Earnings Report

    Analysts’ Recommendations for Merck & Co. after 4Q17

    Merck & Co. (MRK) missed Wall Street analysts’ estimates for revenues but surpassed analysts’ estimates earnings per share.

    By Mike Benson
  • uploads///Part  Graph
    Company & Industry Overviews

    Inside XLV’s Large Caps: Pfizer’s 1Q16 Earnings

    Pfizer recently rose by 2.7% on revenues of $13 billion for 1Q16, as compared to $10.9 billion in 1Q15, which represents a growth of 20% YoY.

    By Peter Neil
  • uploads///Chart
    Company & Industry Overviews

    What Did AGN’s US Medical Aesthetics Segment Contribute in 1Q16?

    Allergan’s US medical aesthetics segment includes facial aesthetics, medical dermatology products, and a wide range of silicone and saline breast implants.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Merck’s Valuation Cheat Sheet for Fiscal 1Q16

    Merck & Co.’s (MRK) current valuation is neither high nor low. Its valuation multiple has followed the industry’s overall trend over the last five years.

    By Mike Benson
  • uploads///ccdafbcfbddefdffcb
    Company & Industry Overviews

    Market Response to EMA Validation of Opdivo Application

    BMY has four key oncology products, including Erbitux, Opdivo, Sprycel, and Yervoy. Two of these contributed more than $1 billion in 2014.

    By Mike Benson
  • uploads///Graph
    Company & Industry Overviews

    Label Expansion Expected to Boost Keytruda’s 2017 Revenue

    On October 24, 2016, the FDA approved Merck & Co’s (MRK) Keytruda as a second-line therapy for patients suffering from non-small cell lung cancer (or NSCLC).

    By Margaret Patrick
  • uploads///close up _
    Earnings Report

    Pfizer Missed Analysts’ Third-Quarter Revenue Estimates

    Pfizer (PFE) released its third-quarter earnings on October 30.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Understanding the Revenue Fall in AstraZeneca’s Largest Segment in 3Q16

    AstraZeneca’s (AZN) CVMD (Cardiovascular and Metabolic Disease) segment contributed nearly 32.4% of total company revenues in 3Q16.

    By Mike Benson
  • uploads///Graph
    Miscellaneous

    Bristol-Myer Squibb’s Opdivo Is Keytruda’s Strong Competitor

    the U.S. Food and Drug Administration accepted the filing of a supplemental Biologics License Application for Bristol-Myers Squibb’s Opdivo.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    What Could Expand Keytruda’s Revenues?

    In addition to the US market, Merck’s (MRK) Keytruda has been approved in more than 50 international markets for metastatic melanoma.

    By Margaret Patrick
  • uploads///Chart
    Company & Industry Overviews

    Merck’s Gardasil and What It Could Mean

    Total sales from Merck’s Gardasil during 3Q16 reached $860 million, a rise of ~38% over the $625 million in 3Q15.

    By Mike Benson
  • uploads///syringe _
    Company & Industry Overviews

    Assessing Novartis’s Performance in October So Far

    Novartis’s ADR (American depositary receipt) has fallen ~1.0% to date in October, while it’s risen nearly 3.3% in the last month.

    By Mike Benson
  • uploads///Graph
    Earnings Report

    Venclexta Witnessed Healthy Demand Trends in 1Q17

    AbbVie’s (ABBV) Venclexta was approved by the FDA on April 11, 2016. AbbVie has also successfully launched Venclexta in Germany and France.

    By Margaret Patrick
  • uploads///Graph
    Earnings Report

    Inside Celgene’s Revlimid: Strong Patient Demand in 4Q16

    After the approval of the drug as a therapy for newly diagnosed multiple myeloma, Celgene’s Revlimid has witnessed rapid growth in market share worldwide.

    By Margaret Patrick
  • uploads///Analysts ratings
    Company & Industry Overviews

    Novartis on the Street: Analysts’ Recommendations in November

    Of the three analysts tracking Novartis in November 2017, one recommends a “strong buy,” while two recommend a “hold.”

    By Daniel Collins
  • uploads///Select Generic Pharma Companies Sales by Geo
    Healthcare

    What Are Biosimilars and Why Do They Benefit Generic Pharma?

    BUTCHER: Going back to what you said about generics being a cheaper alternative, why are they cheaper? DUFFY: The barriers to generic markets are usually a lot lower. If we look at the United States, back in 1984 they passed the Hatch-Waxman Act and essentially what this did was allow for an expedited approval process […]

    By VanEck
  • uploads///Novavax RSV Pipeline
    Company & Industry Overviews

    Exploring Novavax’s Vaccine Candidates for RSV

    According to Novavax, ~64.0 million RSV infections occur every year on a global basis. The global cost of RSV exceeds $88.0 billion.

    By Kenneth Smith
  • uploads///Graph
    Earnings Report

    AbbVie’s Viekira Pak Saw Weaker-than-Expected Performance

    Viekira Pak managed to earn revenues worth about $414 million in 1Q16. The drug’s sales in the US market, however, fell YoY (year-over-year) by about 9.3% and reached $125 million in 1Q16.

    By Margaret Patrick
  • uploads///PFE MDVN deal
    Company & Industry Overviews

    What’s the Story behind the Pfizer-Medivation Deal?

    Medivation’s portfolio complements Pfizer’s existing oncology portfolio that includes solid tumors, hematology, and immunology-oncology.

    By Jillian Dabney
  • uploads///pill _
    Company & Industry Overviews

    Why Incyte Stock Fell ~9% on April 24

    On April 24, Incyte (INCY) stock fell ~9% on news regarding its drug Baricitinib, which is under FDA review.

    By Sarah Collins
  • uploads///Chart
    Company & Industry Overviews

    AstraZeneca and Its Oncology Segment’s Growth in 2Q16

    AstraZeneca’s (AZN) oncology segment is another key focus area. The segment’s contribution increased to more than 15% in 2Q16.

    By Mike Benson
  • uploads///Growth
    Earnings Report

    Johnson & Johnson’s 3Q15 Changes in Growth Rate

    Foreign exchange rates seem to have had a negative impact on Johnson & Johnson’s growth rate since ~50% of total revenues are reported from sales outside the US.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    What to Expect from Pfizer’s 2Q16 Earnings

    In Pfizer’s 2Q16 results, analysts expect to see EPS (or earnings-per-share) of $0.62 and revenues of ~$13.0 billion for 2Q16. The company has surpassed Wall Street analysts’ estimates for EPS over the last few quarters.

    By Mike Benson
  • uploads///freestocks org  unsplash
    Company & Industry Overviews

    Merck and AstraZeneca Announced EMA Approval for Lynparza

    Lynparza (olaparib) is a poly(ADP-ribose) polymerase inhibitor, or PARP inhibitor, and part of Merck & Co. (MRK) and AstraZeneca’s (AZN) global strategic oncology collaboration.

    By Mike Benson
  • uploads///Emend Temodar Revenues
    Company & Industry Overviews

    How Merck’s Oncology Drugs Emend and Temodar Could Perform in 2017

    In 2016, Merck’s (MRK) Emend reported revenues of around $549 million, which reflected 3% year-over-year growth.

    By Daniel Collins
  • uploads///attractive product profile
    Company & Industry Overviews

    What’s behind Biogen Buyout Rumors?

    Since early August 2016, there have been rumors of a likely buyout of Biogen (BIIB) by one of the many interested suitors in the biotechnology industry.

    By Sarah Collins
  • uploads///Graph
    Company & Industry Overviews

    Amgen: Exploring Opportunities in the Bone Segment

    Amgen’s Prolia is the leading brand for treating postmenopausal osteoporosis, or PMO, in women with a high risk of bone fracture.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    AbbVie Hopes to Commercialize Next-Generation HCV Regimen by 2017

    AbbVie (ABBV) plans to complete its Phase 3 registrational program for investigational next-generation Hepatitis C virus (or HCV) therapy by 2016.

    By Margaret Patrick
  • Healthcare

    Why AstraZeneca’s oncology pipeline is attractive to Pfizer

    Pfizer (PFE) is seeking to expand its oncology franchise and a combination with AstraZeneca (AZN) would be meaningful due to the latter’s pipeline of cancer drugs.

    By Samantha Nielson
  • uploads///PE ratio
    Earnings Report

    Key Factors That Impact Johnson & Johnson’s Forward Valuation

    Two factors expected to impact Johnson & Johnson’s forward valuation are increasing competition for Olysio and further decline in international revenues.

    By Nicole Sario
  • uploads///Chart  GSK
    Company & Industry Overviews

    How GlaxoSmithKline Stock Performed in 1Q18

    GlaxoSmithKline stock has risen ~6.4% in 1Q18, while its stock has risen ~12.6% YTD (year-to-date) as of April 6, 2018.

    By Mike Benson
  • uploads///pina messina  unsplash
    Company & Industry Overviews

    Eli Lilly’s Valuation on May 17

    On May 17, Eli Lilly was trading at a forward PE multiple of 15.2x, which compares to the industry average of 13.6x.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    GlaxoSmithKline Increases Top Line in 2Q16

    GlaxoSmithKline (GSK) reported a 10.9% increase in its top line in its 2Q16 earnings on July 27, 2016. It met Wall Street analysts’ estimates for revenues and EPS.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Analyzing Johnson & Johnson’s 1Q18 Profitability

    Johnson & Johnson (JNJ) reported revenues of $20.0 billion during 1Q18, 12.6% growth as compared to revenues of $17.8 billion during 1Q17.

    By Mike Benson
  • uploads///dna _
    Company & Industry Overviews

    European Medicines Agency Validates Merck’s Keytruda Combo

    Merck’s (MRK) Keytruda (pembrolizumab) is approved to treat various forms of cancer.

    By Mike Benson
  • uploads///DIABETES
    Company & Industry Overviews

    Johnson & Johnson Gets FDA Approval for Type 2 Diabetes Drug

    On September 21, 2016, the FDA approved Jannsen Pharmaceuticals’ Invokamet XR for the treatment of adults suffering from Type 2 diabetes.

    By Sarah Collins
  • uploads///Van Eck Video
    Macroeconomic Analysis

    What Are Generic Drugs and Why Are They Important?

    TOM BUTCHER: What are generic drugs, and why are they important? JAMES DUFFY: Generic drugs are drugs that are comparable to their brand-name counterparts. They are comparable in terms of the dosage, effectiveness, and intended use. Generics are important because they are essentially a less-expensive alternative to their brand-name counterparts. This, of course, is expected […]

    By VanEck
  • uploads///RD
    Company & Industry Overviews

    What Were Pfizer’s Major Achievements in 2016?

    During 2016, Pfizer (PFE) succeeded in expanding its label for Ibrance, its breast cancer treatment.

    By Jillian Dabney
  • uploads///Chart
    Earnings Report

    Novartis Will Report Its 4Q15 Earnings on January 27

    Novartis is set to release its 4Q15 and full-year 2015 earnings on January 27, 2016. Analysts estimate an EPS of $1.32 for 4Q15.

    By Mike Benson
  • uploads///Diabetes
    Company & Industry Overviews

    Januvia and Janument: An Update on Merck’s Diabetes Franchise after 2Q17

    In 2Q17, Merck’s (MRK) Januvia generated revenues of around $948 million, which reflected an ~11% decline on a year-over-year basis and 13% growth on a quarter-over-quarter basis.

    By Daniel Collins
  • uploads///pharma division performance
    Earnings Report

    Sales Performance Analysis of Roche’s Pharmaceuticals Division

    Roche Holding (RHHBY) generated ~78% of its group sales from the pharmaceuticals division.

    By Jillian Dabney
  • uploads///Graph
    Company & Industry Overviews

    Durvalumab and Tagrisso May Boost AstraZeneca’s Revenues in 2017

    On December 9, 2016, the FDA accepted for review its first-ever biologics license application (or BLA) submitted by AstraZeneca (AZN).

    By Margaret Patrick
  • uploads///pipeline
    Company & Industry Overviews

    Pfizer Has Strong Track Record since 2010

    As of November 1, Pfizer had ~94 projects in various development stages. More than 40% of these projects are in phase three or the registration phase.

    By Jillian Dabney
  • uploads///Graph
    Company & Industry Overviews

    Novartis Focuses on Portfolio Prioritization to Boost Profitability

    To ensure long-term relevance as well as quick adaptability to changing market needs, Novartis (NVS) is focusing on five major initiatives in 2017.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Opdivo Is a Key Growth Driver for Bristol-Myers Squibb in 2016

    On November 10, 2016, the FDA approved Opdivo as a treatment option for patients suffering with recurring or metastatic squamous cell carcinoma of the head and neck (or SCCHN).

    By Margaret Patrick
  • uploads///Interferon revenues
    Company & Industry Overviews

    Biogen’s Interferon Therapies Could Witness Modest Fall in 2017

    In 2016, Biogen’s (BIIB) interferon therapies, Avonex and Plegridy, together reported revenues of around $2.8 billion, which reflected a drop of ~6% on a year-over-year (or YoY) basis.

    By Daniel Collins
  • uploads///joshua coleman  unsplash
    Earnings Report

    Sanofi Misses Wall Street Estimates for 1Q18 Revenues

    Sanofi (SNY) missed Wall Street analysts’ estimates for revenues today but beat estimates for earnings per share.

    By Mike Benson
  • uploads///Portfolio Composition of Some US Equity Mutual Funds
    Company & Industry Overviews

    What Were the Overall Trends in Large-Cap Mutual Funds Last Year?

    Most of the large-cap mutual funds have the information technology sector as their top choice.

    By David Ashworth
  • uploads///Graph
    Company & Industry Overviews

    AbbVie Strengthens Its Position in the Virology Segment

    In addition to Humira, AbbVie also offers several virology drugs targeting diseases such as hepatitis C, HIV, and respiratory syncytial virus.

    By Margaret Patrick
  • uploads///Chart
    Earnings Report

    What to Expect from Johnson & Johnson’s 4Q15 Earnings

    Johnson & Johnson has returned nearly 1.2% year-to-date while Sanofi, Merck, and Novartis have returned ~0.5%, -4.4%, and -3.5%, respectively.

    By Mike Benson
  • uploads///Graph
    Company & Industry Overviews

    What Will Be a Key Driver of Biogen’s Future Valuations?

    Biogen’s investigational Alzheimer’s disease drug, aducanumab, is one of the four therapies accepted in the EMA’s Priority Medicines program (or PRIME).

    By Margaret Patrick
  • uploads///Graph
    Earnings Report

    Medicaid Restrictions Are Affecting Gilead’s Hepatitis C Drug Sales

    Since the launch of Sovaldi in late 2013, Gilead Sciences has managed to treat about 1,000,000 hepatitis C (or HCV) patients globally.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    AstraZeneca May Witness a Fall in 2017 Net Profit Margin

    Wall Street analysts have projected AstraZeneca’s (AZN) 2017 net profit margins at about 12.2%, which is lower by 300 basis points on a YoY basis.

    By Margaret Patrick
  • uploads///Chart
    Company & Industry Overviews

    Other Drugs for Non-small Cell Lung Cancer

    Approximately 85% of all lung cancers in the United States are non-small cell lung cancers, and 10% to 15% of these are EGFR mutation-positive.

    By Mike Benson
  • uploads///Graph
    Company & Industry Overviews

    Tagrisso Expected to Be a Key Growth Driver for AstraZeneca in 2017

    Launched in Japan in 2Q16, AstraZeneca’s (AZN) 1Q17 revenues for Tagrisso approached $39 million in this major emerging market.

    By Margaret Patrick
  • uploads///Immunology Oncology
    Company & Industry Overviews

    A Look into Merck’s Immunology and Oncology Portfolio

    In 1H17, Remicade generated revenues of around $437 million, which is a 37% decline year-over-year.

    By Daniel Collins
  • uploads///dna _
    Company & Industry Overviews

    Merck’s Relebactam Met Primary Endpoints in Phase 3 Study

    Merck’s Relebactam is an investigational drug for the treatment of certain forms of imipenem-non-susceptible bacterial infections.

    By Mike Benson
  • uploads///Graph
    Miscellaneous

    FDA Granted Breakthrough Therapy Status to Merck’s HCV Therapy

    The U.S. Food and Drug Administration (or FDA) granted breakthrough therapy designation to Merck’s (MRK) grazoprevir/elbasvir (100mg/50mg) combination therapy.

    By Margaret Patrick
  • uploads///virus _
    Earnings Report

    Bristol-Myers Squibb’s 1Q18 Earnings Beat Wall Street Estimates

    Bristol-Myers Squibb beat Wall Street analysts’ estimates for earnings per share and revenues in 1Q18.

    By Mike Benson
  • uploads///Chart
    Miscellaneous

    Teva’s Respiratory Drugs Contribute 11% to Specialty Medicines

    Teva’s respiratory drugs franchise provides solutions for asthma, COPD, and allergic rhinitis. Respiratory drugs contributed nearly 11% of total revenues for Teva’s Specialty Medicines in 2014.

    By Mike Benson
  • uploads///BEAM
    Financials

    In high spirits? Why did Tudor open position in Beam?

    Paul Tudor Jones II in 1982 founded Tudor Investment Corporation, which is today a leading asset management firm headquartered in Greenwich, Connecticut. The Tudor Group, consisting of Tudor Investment Corporation and its affiliates, is involved in active trading, investing and research in assets across fixed income, currencies, equities and commodities asset classes and related derivative […]

    By Samantha Nielson
  • uploads///Noxafil and Cubicin
    Company & Industry Overviews

    Understanding the Performance of Merck’s Hospital Acute Care Drugs Noxafil and Cubicin

    In 4Q17, Merck’s (MRK) Cubicin reported revenues of $92 million, which was ~23% lower on a YoY (year-over-year) basis.

    By Daniel Collins
  • uploads///Graph
    Company & Industry Overviews

    Xtandi’s Prescription Volumes Continue to Rise in 2017

    In this series, we’ll look at Pfizer’s main revenue drivers in 2017, and what could steer its performance in 2018.

    By Margaret Patrick
  • uploads///projections
    Earnings Report

    Johnson & Johnson’s Q2 2018 Earnings Estimates

    As per Wall Street analysts estimates, Johnson & Johnson (JNJ) is expected to report adjusted EPS (earnings per share) of $2.07 in the second quarter of fiscal 2018.

    By Sarah Collins
  • uploads///dna _
    Earnings Report

    Pfizer Reports 1Q18 Earnings and Revenue Growth

    Pfizer (PFE) released its 1Q18 earnings today, reporting another strong quarter for the Innovative health business.

    By Mike Benson
  • uploads///chart_ __ _cresemba
    Company & Industry Overviews

    Pfizer Has Received Commercial Rights for Cresemba in Europe

    On June 14, 2017, Pfizer (PFE) announced an agreement with Basilea Pharmaceutica for exclusive commercial rights for Cresemba in Europe.

    By Mike Benson
  • uploads///portfolio
    Company & Industry Overviews

    Ligand Pharmaceuticals’s Portfolio Pyramid as Its Valuation Catalyst

    Ligand Pharmaceuticals’s (LGND) product portfolio has expanded from nine programs in 2008 to 140+ programs in 2016.

    By Jillian Dabney
  • uploads///medical _
    Earnings Report

    Analysts Cut Target Prices on MYL Stock after Its Q2 2018 Results

    Mylan (MYL) reported its Q2 earnings on August 8. On August 13, 13 of 20 surveyed firms still held a “buy” or “strong buy” rating on MYL.

    By Sarah Collins
  • uploads///Article
    Company & Industry Overviews

    Understanding Johnson & Johnson’s Ownership Structure

    As of January 2015, Johnson & Johnson’s ownership structure is dominated by passive investments. They account for more than 80% of the total ownership structure.

    By Mike Benson
  • uploads///jaron nix  unsplash
    Company & Industry Overviews

    Pfizer’s Valuation as of May 22

    Pfizer trades at a forward enterprise-value-to-EBITDA multiple of 10.3x, which is much lower than the industry average of 11.6x.

    By Mike Benson
  • uploads///Graph
    Company & Industry Overviews

    AbbVie’s Rova-T and the Treatment of Small Cell Lung Cancer

    AbbVie (ABBV) expects to secure FDA (U.S. Food & Drug Administration) approval in the third-line plus small cell lung cancer (or SCLC) indication in 2018.

    By Margaret Patrick
  • uploads///RD Generic Pharma
    Macroeconomic Analysis

    Expert Q&A: What to Know Before Investing in Generic Pharma? (Part 2)

    (continued from Part 1) 4. What is the nature of the cash flows for generics companies? Stable, driven by a constant demand for prescription drugs? Or lumpy, driven by growth from drugs coming off patent? The larger companies in this sector tend to have stable, steadier cash flows due to established lineups of approved products. […]

    By VanEck
  • uploads///Analysts recommendation
    Company & Industry Overviews

    Analysts Recommendations for AbbVie in August 2017

    Twenty-one analysts were tracking AbbVie in August 2017. Three analysts suggested a “strong buy,” while seven suggested a “buy.”

    By Daniel Collins
  • uploads///Merck Performance
    Company & Industry Overviews

    How Merck Is Expected to Perform in 2017

    In 1Q17, Merck (MRK) generated revenues of ~$9.4 billion, which reflected 1% YoY growth. Merck expects its GAAP net revenues in fiscal 2017 to reach $39.1 billion–$40.3 billion.

    By Daniel Collins
  • uploads///GUIDANCE
    Company & Industry Overviews

    How’s Gilead Sciences Expected to Perform in 2016?

    Gilead Sciences lowered its guidance for fiscal 2016 due to weak 2Q16 results reported on July 25. It expects its 2016 revenues to be $29.5 billion–$30.5 billion.

    By Sarah Collins
  • uploads///Chart
    Company & Industry Overviews

    Inside Novartis’s Eye Care Performance in 4Q16

    Alcon, NVS’s eye care segment, saw its 4Q16 revenues fall ~2% to ~$1.4 billion, including no change in sales but a -2% impact from foreign exchange.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    How Eli Lilly’s Cardiovascular Products Have Been Faring

    Eli Lilly and Company’s (LLY) Human Pharmaceutical segment includes cardiovascular products such as Cialis, Effient, and other products.

    By Mike Benson
  • uploads///Vaccine revenues
    Company & Industry Overviews

    How Pfizer’s Vaccine Franchise Is Positioned in 2017

    In 2016, Pfizer’s (PFE) Prevnar 13 reported revenues of ~$5.7 billion, which reflected a ~8% decline on a YoY (year-over-year) basis.

    By Daniel Collins
  • uploads///pill _
    Healthcare

    These Pharma Stocks Offer the Most Upside Potential

    In 2018, stock markets, especially in the pharmaceutical sector, have seen heightened volatility.

    By Kenneth Smith
  • uploads///PD  class action
    Company & Industry Overviews

    Brace Yourself: AstraZeneca Could Be a Fourth Entrant into the PD-1/PD-L1 Drug Class

    The PD-1 (programmed death-1)/PD-L1 (programmed death-ligand 1) class consists of Bristol-Myers Squibb’s Opdivo, Merck’s Keytruda, and Roche’s Tecentriq.

    By Jillian Dabney
  • uploads///Costs
    Earnings Report

    Johnson & Johnson’s Profitability Improves in 2Q15

    Johnson & Johnson’s net profit margin improved to 25.4% for 2Q15 compared to 22.2% for 2Q14 due to the divestiture of some low profitability products and improved sales of high profitability products.

    By Mike Benson
  • uploads///Graph
    Earnings Report

    What Drove Gilead Sciences’ Hepatitis C Portfolio in 3Q15?

    Gilead Sciences’ (GILD) hepatitis C (or HCV) portfolio is expected to continue driving the company’s revenues and net profit margins in 3Q15.

    By Margaret Patrick
  • © Copyright 2022 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.